Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 5, 2012, Pages 888-892

  Deguchi, Ryuzo ^a   Nakaminami, Hidemasa ^b   Rimbara, Emiko ^b   Noguchi, Norihisa ^b   Sasatsu, Masanori ^b   Suzuki, Takayoshi ^a   Matsushima, Masashi ^a   Koike, Jun ^a   Igarashi, Muneki ^a   Ozawa, Hideki ^a   Fukuda, Ryuki ^a   Takagi, Atsushi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Clarithromycin resistant strain; Helicobacterpylori; Helicobacterpylori eradication therapy; Lactobacillus gasseri; Probiotics

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; RABEPRAZOLE; RNA 23S; YOGHURT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; DIARRHEA; DNA SEQUENCE; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; GENE MUTATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LACTOBACILLUS GASSERI; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; UREA BREATH TEST;

EID: 84860241821     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06985.x     Document Type: Article

References (22)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 323: 1311-15.
2. Asaka M, Kimura T, Kudo M etal. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992; 102: 760-6.
3. Asaka M, Kato M, Sugiyama T etal. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J. Gastroenterol. 2003; 38: 339-47.
4. Uemura N, Okamoto S, Yamamoto S etal. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784-9.
5. Kabir AMA, Aiba Y, Takagi A, Kamiya S, Miwa T, Koga Y. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut 1997; 41: 49-55.
6. Aiba Y, Suzuki N, Kabir AMA, Takagi A, Koga Y. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am. J. Gastroenterol. 1998; 93: 2097-101.
7. Sakamoto I, Igarashi M, Kimura K, Takagi A, Miwa T, Koga Y. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J. Antimicrob. Chemother. 2001; 47: 709-10.
8. Cruchet S, Obregon MC, Salazar G, Diaz E, Gotteland M. Effect of the ingestion of dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization of children. Nutrition 2003; 19: 716-21.
9. Pantoflickova D, Corthesy-Theulaz I, Dorta G etal. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment. Pharmacol. Ther. 2003; 18: 805-13.
10. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment. Pharmacol. Ther. 2007; 25: 155-68.
11. Ushiyama A, Takana K, Aiba Y etal. Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2003; 18: 986-91.
12. Noguchi N, Rimbara E, Kato A etal. Detection of mixed clarithromycin-resistant and -susceptible Helicobacter pylori using nested PCR and direct sequencing of DNA extracted from faeces. J. Med. Microbiol. 2007; 56: 1174-80.
13. Kuwayama H, Asaka M, Sugiyama T etal. The Japan Rabeprazole Study Group. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. Aliment. Pharmacol. Ther. 2007; 25: 1105-13.
14. Ito M, Tanaka S, Kim S etal. A combination of the Helicobacter pylori stool antigen test and urea breath test is useful for clinical evaluation of eradication therapy: a multicenter study. J. Gastroenterol. Hepatol. 2005; 20: 1241-5.
15. Deguchi R, Matsushima M, Suzuki T etal. Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy. J. Gastroenterol. 2009; 44: 713-16.
16. Szajewska H, Albrecht P, Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled trial: effect of Lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J. Pediatr. Gastroenterol. Nutr. 2009; 48: 431-6.
17. Kim MN, Kim N, Lee SH etal. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008; 13: 261-8.
18. Sheu B-S, Wu J-J, Lo C-Y etal. Impact of supplement with Lactobacillus- and Bifidobacterium- containing yogurt on triple therapy for Helicobacter eradication. Aliment. Pharmacol. Ther. 2002; 16: 1669-75.
19. Sheu B-S, Cheng H-C, Kao A-W etal. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am. J. Clin. Nutr. 2006; 83: 864-9.
20. Crabtree JE, Peichl P, Wyatt JI, Stachl U, Lindley IJD. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand. J. Immunol. 1993; 37: 65-70.
21. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY. Relationship between clinical presentation, Helicobacter pylori, interleukin 1B and 8 production, and cagA status. Gut 1999; 45: 804-11.
22. Tamura A, Kumai H, Nakamichi N etal. Suppression of Helicobacter pylori-induced interleukin-8 production in vitro and within the gastric mucosa by a live Lactobacillus strain. J. Gastroenterol. Hepatol. 2006; 21: 1399-1406.